Video

Scott Solomon from Brigham and Women's Hospital: Building Momentum to Help Heart Failure Patients

Author(s):

As new medications are introduced to the market there can be some hesitation by doctors to make the jump from more traditional treatment options. Moving beyond that has shown benefits for a patient's long term health.

As new medications are introduced to the market there can be some hesitation by doctors to make the jump from more traditional treatment options. Moving beyond that has shown benefits for a patient's long term health.

One such medication being studied in this effort is sacubitril/valsartan, also known as entresto. Scott David Solomon, MD, from Brigham & Women's Hospital and Harvard Medical School discussed the results of the Paradigm-HF trial which studied how the medication can help even "stable" heart failure patients. Solomon said the results of the study showed the benefit of this medication would work when compared to other patients including those ACE inhibitors or ARBs.

Related Videos
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
HCPLive Lipoprotein Apheresis Special Report thumbnail
HCPLive Lipoprotein Apheresis Special Report thumbnail
HCPLive Lipoprotein Apheresis Special Report thumbnail
Linda Gillam, MD, MPH | Credit: Atlantic Health System
Linda Gillam, MD, MPH | Credit: Atlantic Health System
Steve Nissen, MD | Credit: Cleveland Clinic
Harpreet Bhatia, MD: Benefits of Universal Screening for Lp(a) Levels
© 2024 MJH Life Sciences

All rights reserved.